Copenhagen - Delayed Quote DKK

ChemoMetec A/S (CHEMM.CO)

507.50

+1.50

+(0.30%)

At close: 4:59:58 PM GMT+2

Exploring Europe's Undiscovered Gems In May 2025

As the pan-European STOXX Europe 600 Index continues its upward trend, buoyed by easing trade tensions between China and the U.S., small-cap stocks are gaining attention for their potential to outperform in a mixed market environment. With Germany's industrial output surging ahead of new tariffs and the Bank of England adopting a cautious approach to interest rate adjustments, investors are increasingly looking towards undiscovered gems that could thrive amidst these dynamic conditions. In...

Simply Wall St. 18 days ago

CHEMM.CO
+0.30%

ITM.MI

CRBP2.PA
Continued growth in revenue and operating profit

Trading statement for Q3 2024/25 (1 January - 31 March 2025) Continued growth in revenue and operating profit Revenue was up by 26% in the third quarter of 2024/25 to DKK 124.2 million from DKK 98.9 million in the year-earlier period. Growth was driven primarily by sales of products related to the NC platform, reflecting increased activity levels for customers with ongoing clinical trials and approved therapies. The Q3 performance reflected continued growth in sales of both instruments, consumab

GlobeNewswire 27 days ago

CHEMM.CO
+0.30%
3 Undiscovered European Gems Including ChemoMetec

As European markets navigate the turbulence of intensified global trade tensions, with the pan-European STOXX Europe 600 Index recently ending 1.92% lower, investors are increasingly vigilant about the economic landscape and its impact on small-cap stocks. Despite these challenges, there remains potential for discovering promising opportunities within Europe's diverse market, where unique companies like ChemoMetec can offer intriguing prospects for those seeking to identify hidden gems amidst...

Simply Wall St. last month

CHEMM.CO
+0.30%

CRBP2.PA

VIO.BR
Discovering Europe's Undiscovered Gems This March 2025

As Europe navigates the complexities of U.S. trade tariffs and monetary policy uncertainties, the pan-European STOXX Europe 600 Index recently ended 1.23% lower, reflecting broader market caution. In this environment, identifying promising small-cap stocks requires careful consideration of companies with resilient business models and growth potential that can withstand economic fluctuations and geopolitical challenges.

Simply Wall St. 2 months ago

CHEMM.CO
+0.30%

ENGCON-B.ST
Notification of managers' transactions

ANNOUNCEMENT NO. 288 10 February 2025 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them. See the transactions of the Chair of ChemoMetec’s Board of Directors Niels Thestrup in the attached PDF document. For further information, please

GlobeNewswire 3 months ago

CHEMM.CO
+0.30%
Undiscovered Gems To Explore In February 2025

As global markets navigate the complexities of tariff uncertainties and a cooling labor market, small-cap stocks have shown resilience despite broader index declines. With U.S. manufacturing activity expanding for the first time in over two years, investors are increasingly looking towards undiscovered gems that demonstrate strong fundamentals and potential growth amidst these shifting economic landscapes.

Simply Wall St. 3 months ago

CHEMM.CO
+0.30%
Interim report 2024/25 - Solid H1 performance driven by growth in both revenue and earnings

ANNOUNCEMENT NO. 2875 February 2025 Solid H1 performance driven by growth in both revenue and earnings Martin Helbo Behrens, CEO: The growth continued in the second quarter of 2024/25, and revenue for the first half of the year was up to DKK 251.5 million, a year-on-year increase of 26%. Growth was supported by a few large orders for the new XcytoMatic instruments in the wake of the customer validations initiated in the spring of 2024. Concurrently, we maintained our commercial focus in the firs

GlobeNewswire 3 months ago

CHEMM.CO
+0.30%
Upgrade of revenue and operating profit guidance

ANNOUNCEMENT NO. 286 10 January 2025 Upgrade of revenue and operating profit guidance ChemoMetec sustained its positive performance in the second quarter of 2024/25 with better-than-expected sales and order intake. The positive development is supported by the strengthening of the US dollar and continuous optimisation of operating costs. Based on this, the Company now expects revenue for the 2024/25 financial year in the DKK 470-490 million range, up from DKK 460-475 million in the most recent gu

GlobeNewswire 4 months ago

CHEMM.CO
+0.30%
Major shareholder announcement – AIM International Mutual Funds

ANNOUNCEMENT NO. 287 9 December 2024 Major shareholder announcement Major shareholder announcement – AIM International Mutual Funds Pursuant to Section 30 of the Capital Markets Act, it is hereby announced that Invesco Ltd. has informed ChemoMetec A/S that AIM International Mutual Funds (Invesco International Mutual Funds) on 4 December 2024, decreased its holding of voting rights attached to shares and voting rights in ChemoMetec A/S to below 5%, and that the holding thus is below the 5 per cen

GlobeNewswire 5 months ago

CHEMM.CO
+0.30%
Major shareholder announcement – Invesco Ltd.

ANNOUNCEMENT NO. 286 9 December 2024 Major shareholder announcement Major shareholder announcement – Invesco Ltd. Pursuant to Section 30 of the Capital Markets Act, it is hereby announced that Invesco Ltd. has informed ChemoMetec A/S that Invesco Ltd. on 4 December 2024, decreased its holding of voting rights attached to shares and voting rights in ChemoMetec A/S to below 5%, and that the holding thus is below the 5 per cent limit in section 38 of the Capital Markets Act. Additional information

GlobeNewswire 5 months ago

CHEMM.CO
+0.30%
Growth in revenue and operating profit

Trading statement for Q1 2024/25 (1 July - 30 September 2024) Growth in revenue and operating profit Revenue was up 27% in the first quarter of 2024/25 to DKK 115.6 million from DKK 91.1 million in the year-earlier period. The performance reflects growing sales of both instruments, consumables and services. Operating profit (EBITDA) was up 50% in the first quarter to DKK 62.1 million, driven by the revenue growth. The EBITDA margin was 54% for the first quarter. 2024/25Q1 2023/24Q1 Change, %Reve

GlobeNewswire 6 months ago

CHEMM.CO
+0.30%
Closing of acquisition of Ovizio Imaging Systems SA

ANNOUNCEMENT NO. 281 22 October 2024 Closing of acquisition of Ovizio Imaging Systems SA All capital owners have now accepted ChemoMetec's takeover offer, and closing has been completed today and thus the final acquisition of 100% of the capital in the Belgian company Ovizio Imaging Systems SA for the previously announced purchase price of EUR 2,830,000. Additional information Martin Helbo Behrens, CEOTel.: (+45) 48 13 10 20 Kim Nicolajsen, CFOTel.: (+45) 48 13 10 20 About Ovizio Ovizio has deve

GlobeNewswire 7 months ago

CHEMM.CO
+0.30%
Acquisition of Ovizio Imaging Systems SA

ANNOUNCEMENT NO. 280 16 October 2024 Acquisition of Ovizio Imaging Systems SA On the basis of the completed due diligence, ChemoMetec today submitted a binding tender offer for the acquisition of 100% of the shares of Belgian company Ovizio Imaging Systems SA (’Ovizio’). The acquisition price is EUR 2,830,000. The tender offer has already been accepted by shareholders owning more than two thirds of Ovizio, and ChemoMetec is currently in the process of obtaining acceptance from the remaining shar

GlobeNewswire 7 months ago

CHEMM.CO
+0.30%
ChemoMetec’s potential acquisition of Ovizio Imaging Systems SA

ANNOUNCEMENT NO. 278 11 October 2024 ChemoMetec’s potential acquisition of Ovizio Imaging Systems SA As mentioned in company announcement no. 276, ChemoMetec has made an indicative purchase offer for the Belgian company Ovizio Imaging Systems SA. As also stated in the announcement, ChemoMetec expected to complete the due diligence within three weeks and most likely to complete the acquisition, if the outcome was positive. The mentioned due diligence and negotiations on the final share purchase a

GlobeNewswire 7 months ago

CHEMM.CO
+0.30%
Procedure of the Annual General Meeting

ANNOUNCEMENT NO. 277 10 October 2024 Procedure of the Annual General Meeting The Annual General Meeting of ChemoMetec A/S was held on 10 October 2024 at 5.30 p.m. at Nordsjællands KonferenceCenter. At the Annual General Meeting, the Board of Directors' report on the company's activities during the past year was presented, the annual report for 2023/24 was approved, and the Board of Directors and the Executive Board were granted discharge. The Annual General Meeting approved the proposal of the B

GlobeNewswire 7 months ago

CHEMM.CO
+0.30%
ChemoMetec makes offer to buy Ovizio Imaging Systems SA

ANNOUNCEMENT NO. 276 20 September 2024 ChemoMetec makes offer to buy Ovizio Imaging Systems SA ChemoMetec has submitted an indicative offer to buy Belgian company Ovizio Imaging Systems (‘Ovizio’), which has been accepted by the company’s group of owners. ChemoMetec now has three weeks to carry out a due diligence, and if the outcome of this is positive, ChemoMetec will most likely proceed with the acquisition. Ovizio has developed a cell counter based on holographic microscopy. The instrument i

GlobeNewswire 8 months ago

CHEMM.CO
+0.30%
Annual Report 2023/24 - Strengthened commercial focus after challenging year

ANNOUNCEMENT NO. 273 11 September 2024 Annual Report 2023/24 (1 July 2023 - 30 June 2024) Strengthened commercial focus after challenging year ChemoMetec’s revenue fell by 8% in 2023/24 to DKK 407.4 million, and operating profit (EBITDA) was down by 26% to DKK 186.2 million. Revenue was adversely affected by a 35% decline in sales of instruments, while sales of consumables and services were up by 13% in total. During the year, ChemoMetec initiated a gradual launch of the XcytoMatic 40 and XcytoM

GlobeNewswire 8 months ago

CHEMM.CO
+0.30%
Guidance for the 2024/25 financial year

ANNOUNCEMENT NO. 272 11 September 2024 Guidance for the 2024/25 financial year ChemoMetec has today approved the annual report for 2023/24, including the guidance for 2024/25, which is considered inside information. For 2024/25, ChemoMetec expects revenue in the range of DKK 435-450 million (2023/24: DKK 407.4 million) and EBITDA in the range of DKK 216-223 (2023/24: DKK 186.2 million). The annual report for 2023/24, which is released along with this announcement, sets out the underlying assumpt

GlobeNewswire 8 months ago

CHEMM.CO
+0.30%
Major shareholder announcement – BlackRock, Inc.

4 July 2024 Major shareholder announcement – BlackRock, Inc. ANNOUNCEMENT NO. 271 Major shareholder announcement – BlackRock, Inc. Pursuant to Section 30 of the Capital Markets Act, it is hereby announced that BlackRock, Inc. has informed ChemoMetec A/S that BlackRock Investment Management (UK) Limited on 3 July 2024, increased its holding of voting rights attached to shares and voting rights in ChemoMetec A/S to above 10%, and that the holding thus exceeds the 10 per cent limit in section 38 of

GlobeNewswire 10 months ago

CHEMM.CO
+0.30%
Preliminary revenue figures for the 2023/24 financial year

ANNOUNCEMENT NO. 270 2 July 2024 Preliminary revenue figures for the 2023/24 financial year In the fourth quarter of the 2023/24 financial year, ChemoMetec's revenue was DKK 109.2 million, corresponding to a growth of 13.5% from the year-earlier period. The revenue for the 2023/24 financial year was DKK 407.4 million against DKK 442.3 million the previous year, corresponding to a decrease of 7.9%. The revenue in 2023/24 is thus in line with the latest disclosed guidance for the revenue of DKK 40

GlobeNewswire 10 months ago

CHEMM.CO
+0.30%

Performance Overview

Return	CHEMM.CO	OMX Copenhagen 25 Index (^OMXC25)
YTD	+4.38%	-1.02%
1-Year	+50.31%	-10.98%
3-Year	-31.95%	+4.91%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ChemoMetec A/S (CHEMM.CO)

Exploring Europe's Undiscovered Gems In May 2025

Continued growth in revenue and operating profit

3 Undiscovered European Gems Including ChemoMetec

Discovering Europe's Undiscovered Gems This March 2025

Notification of managers' transactions

Undiscovered Gems To Explore In February 2025

Interim report 2024/25 - Solid H1 performance driven by growth in both revenue and earnings

Upgrade of revenue and operating profit guidance

Major shareholder announcement – AIM International Mutual Funds

Major shareholder announcement – Invesco Ltd.

Growth in revenue and operating profit

Closing of acquisition of Ovizio Imaging Systems SA

Acquisition of Ovizio Imaging Systems SA

ChemoMetec’s potential acquisition of Ovizio Imaging Systems SA

Procedure of the Annual General Meeting

ChemoMetec makes offer to buy Ovizio Imaging Systems SA

Annual Report 2023/24 - Strengthened commercial focus after challenging year

Guidance for the 2024/25 financial year

Major shareholder announcement – BlackRock, Inc.

Preliminary revenue figures for the 2023/24 financial year

Performance Overview